Anavex Life Sciences Corp (NASDAQ: AVXL) has released data that showed ANAVEX2-73 to be a preventive medication in Alzheimer’s disease pharmacological model.
ANAVEX2-73 showed protective ability against AD
In the Aβ25-35 peptide Alzheimer’s disease model in mice, ANAVEX2-73 pre-treatment, given once daily for a week before the Aβ challenge, proved to be protective. Aβ25-35 -induced biomarker-associated cognitive impairments were examined one week after the Aβ shock, during which no further ANAVEX2-73 therapy was given and ANAVEX®2-73 and dose-dependently protected the mice.
The activation of the sigma-1 receptor (SIGMAR1 happens through ANAVEX®2-73), with the activation, appears to restore full housekeeping function in the body. It is critical for r brain cell homeostasis restoration and encouraging neuroplasticity. 1 SIGMAR1 also induces autophagy, which leads to the destruction of the amyloid-beta precursor protein (APP), preventing the development of Aβ.
Anavex CEO said, “We are excited about this data, which indicates the potential expansion for the ANAVEX®2-73 platform to find an effective Alzheimer’s prevention therapy, which might benefit the entire field. In addition to finding treatment options for Alzheimer’s disease, we are also striving to find effective prevention therapies for this devastating disease, and this data might help advance this endeavor to address an area of high unmet medical need.”
The latest results confirm past study results
A previous publication on Neuropharmacology showed that ANAVEX2-73 treated patients had improved cognition scores or more than 2.0 points in MMSE with a 9% average improvement at week 57 from baseline. In addition, the same patients showed ADCS-ADL improvement by +4.9 points with a t% average improvement at week 57 from baseline.
At week 70, the same patients’ MMSE scores improved by +3.0, a 14 percent improvement from baseline, equal to a computed ADAS-Cog score change of -5.1, according to an extension study (ANAVEX2-73-003). In addition, ANAVEX®2-73 improved ADCS-ADL by +6.0 points in these same patients, an improvement of 8% at 70 weeks from baseline.